Pathology: es-BC - HER2 positive - (neo)adjuvant (NA);
es-BC - HER2 positive - (neo)adjuvant (NA) | ||
GeparQuinto, 2012 | ||
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | 1 | T1 |
lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | 0 | T0 |